Search research articles
Contact Us
Filters
Showing results (141-150 of 308) with videos related to
Page
of 31
Sort By:
Leukemia
|
August 19, 2021
Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group
Carla Damaschin, Helen Goergen, Stefanie Kreissl, et al.
Journal of Cancer Research and Clinical Oncology
|
February 19, 2022
Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma
Max S Topp, Herbert Eradat, Axel Florschütz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 7, 2010
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial
Andreas Engert, Andreas Josting, Heinz Haverkamp, et al.
Blood
|
October 21, 2015
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment
Gerhard Zugmaier, Nicola Gökbuget, Matthias Klinger, et al.
The Lancet. Oncology
|
November 15, 2017
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group
Dennis A Eichenauer, Annette Plütschow, Stefanie Kreissl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 3, 2020
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
Max S Topp, Johannes Duell, Gerhard Zugmaier, et al.
Blood
|
April 19, 2015
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
Achim Rothe, Stephanie Sasse, Max S Topp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2018
Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group
Stephanie Sasse, Helen Goergen, Annette Plütschow, et al.
Blood Advances
|
October 25, 2019
Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia
Nicola Gökbuget, Hagop M Kantarjian, Monika Brüggemann, et al.
Blood
|
May 18, 2012
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
Matthias Klinger, Christian Brandl, Gerhard Zugmaier, et al.
Page
of 31
Search research articles
Search
Showing results (141-150 of 308) with videos related to
Sort By:
Page
of 31
Leukemia
|
August 19, 2021
Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group
Carla Damaschin, Helen Goergen, Stefanie Kreissl, et al.
Journal of Cancer Research and Clinical Oncology
|
February 19, 2022
Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma
Max S Topp, Herbert Eradat, Axel Florschütz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 7, 2010
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial
Andreas Engert, Andreas Josting, Heinz Haverkamp, et al.
Blood
|
October 21, 2015
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment
Gerhard Zugmaier, Nicola Gökbuget, Matthias Klinger, et al.
The Lancet. Oncology
|
November 15, 2017
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group
Dennis A Eichenauer, Annette Plütschow, Stefanie Kreissl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 3, 2020
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
Max S Topp, Johannes Duell, Gerhard Zugmaier, et al.
Blood
|
April 19, 2015
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
Achim Rothe, Stephanie Sasse, Max S Topp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2018
Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group
Stephanie Sasse, Helen Goergen, Annette Plütschow, et al.
Blood Advances
|
October 25, 2019
Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia
Nicola Gökbuget, Hagop M Kantarjian, Monika Brüggemann, et al.
Blood
|
May 18, 2012
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
Matthias Klinger, Christian Brandl, Gerhard Zugmaier, et al.
Page
of 31